Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 153-160

  Liu, Zebing ^a,b   Yang, Yu ^a   Zhang, Youyuan ^a   Ye, Xuanguang ^a   Wang, Li ^a   Xu, Guoxiong ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Progression; Proliferation; Stomatin like protein 2; TGF ; Thyroid cancer

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; STOMATIN; STOMATIN LIKE PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CARCINOMA CELL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TRANSCRIPTION REGULATION; UPREGULATION; YOUNG ADULT;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; BLOOD PROTEINS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RNA, MESSENGER; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84891918756     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2833     Document Type: Article

References (34)

1. Boone RT, Fan CY and Hanna EY: Well-differentiated carcinoma of the thyroid. Otolaryngol Clin North Am 36: 73-90, 2003.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428, 1994.
4. Schlumberger MJ: Papillary and follicular thyroid carcinoma. N Engl J Med 338: 297-306, 1998.
5. + regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 95: 2325-2333, 2010.
6. Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M and Karpuzoglu G: Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 111: 439-443, 2003.
7. Wang Y and Morrow JS: Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem 275: 8062-8071, 2000.
8. Christie DA, Kirchhof MG, Vardhana S, Dustin ML and Madrenas J: Mitochondrial and plasma membrane pools of stomatin-like protein 2 coalesce at the immunological synapse during T cell activation. PLoS One 7: e37144, 2012.
9. Owczarek CM, Treutlein HR, Portbury KJ, Gulluyan LM, Kola I and Hertzog PJ: A novel member of the STOMATIN/EPB72/mec-2 family, stomatin-like 2 (STOML2), is ubiquitously expressed and localizes to HSA chromosome 9p13.1. Cytogenet Cell Genet 92: 196-203, 2001.
10. Green JB and Young JP: Slipins: ancient origin, duplication and diversification of the stomatin protein family. BMC Evol Biol 8: 44, 2008.
11. Tondera D, Grandemange S, Jourdain A, et al: SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J 28: 1589-1600, 2009.
12. Christie DA, Lemke CD, Elias IM, et al: Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial biogenesis and function. Mol Cell Biol 31: 3845-3856, 2011.
13. Da Cruz S, Parone PA, Gonzalo P, et al: SLP-2 interacts with prohibitins in the mitochondrial inner membrane and contributes to their stability. Biochim Biophys Acta 1783: 904-911, 2008.
14. Zhang L, Ding F, Cao W, et al: Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res 12: 1639-1646, 2006.
15. Song L, Liu L, Wu Z, et al: Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-κB/MMP-9 pathway. J Pathol 226: 534-543, 2012.
16. Cao WF, Zhang LY, Liu MB, Tang PZ, Liu ZH and Sun BC: Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum Pathol 38: 747-752, 2007.
17. Cao W, Zhang B, Liu Y, et al: High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol 128: 430-436, 2007.
18. Han CL, Chen JS, Chan EC, et al: An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol Cell Proteomics 10: M110.003087, 2011.
19. Liu D, Zhang L, Shen Z, et al: Increased levels of SLP-2 correlate with poor prognosis in gastric cancer. Gastric Cancer: Jan 31, 2013 (Epub ahead of print).
20. Wang Y, Cao W, Yu Z and Liu Z: Downregulation of a mitochondria associated protein SLP-2 inhibits tumor cell motility, proliferation and enhances cell sensitivity to chemotherapeutic reagents. Cancer Biol Ther 8: 1651-1658, 2009.
21. Eloy C, Santos J, Cameselle-Teijeiro J, Soares P and Sobrinho- Simões M: TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch 460: 587-600, 2012.
22. Knauf JA, Sartor MA, Medvedovic M, et al: Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30: 3153-3162, 2011.
23. Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED and Wynford-Thomas D: Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2: 149-155, 1990.
24. Müssig K, Wehrmann T, Dittmann H, et al: Expression of the proliferation marker Ki-67 associates with tumor staging and clinical outcome in differentiated thyroid carcinomas. Clin Endocrinol 77: 139-145, 2012.
25. Kimura ET, Kopp P, Zbaeren J, et al: Expression of transforming growth factor β1, β2, and β3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid 9: 119-125, 1999.
26. Cui Z, Zhang L, Hua Z, Cao W, Feng W and Liu Z: Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol Rep 17: 829-833, 2007.
27. + T cell responses. J Immunol 189: 4349-4360, 2012.
28. Da Cruz S, De Marchi U, Frieden M, Parone PA, Martinou JC and Demaurex N: SLP-2 negatively modulates mitochondrial sodium-calcium exchange. Cell Calcium 47: 11-18, 2010.
29. Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al: The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97: E878-E887, 2012.
30. Cao W, Zhang B, Ding F, Zhang W, Sun B and Liu Z: Expression of SLP-2 was associated with invasion of esophageal squamous cell carcinoma. PLoS One 8: e63890, 2013.
31. Massagué J: TGFβ in cancer. Cell 134: 215-230, 2008.
32. Montero-Conde C, Martin-Campos JM, Lerma E, et al: Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27: 1554-1561, 2008.
33. Vasko V, Espinosa AV, Scouten W, et al: Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 104: 2803-2808, 2007.
34. V600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69: 8317-8325, 2009.